Infant Bacterial Therapeutics AB (publ) announced the Nomination Committee for the Annual General Meeting 2024 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Per-Erik Andersson (Chairman of the Nomination Committee), appointed by the shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second shareholder, and Jannis Kitsakis, appointed by the third shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
88.4 SEK | +0.68% | +4.36% | +1.11% |
1st Jan change | Capi. | |
---|---|---|
+1.11% | 108M | |
+3.82% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- IBT B Stock
- News Infant Bacterial Therapeutics AB
- Infant Bacterial Therapeutics AB Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024